A growing number of successful injunctions against trade unions to halt strikes is attracting increasing media attention. Arguments will undoubtedly continue about whether such injunctions are undemocratic, or simply reflec...

A growing number of successful injunctions against trade unions to halt strikes is attracting increasing media attention. Arguments will undoubtedly continue about whether such injunctions are undemocratic, or simply reflec...

The European guide to strikes and other industrial action has been created by Eversheds Sutherland to provide you with a quickand easy reference when responding to threats of industrial action in 15 European countries. Click here to download the pub...

With little consensus on how best to balance public health against social and economic needs, societies are feeling their way through the trade-offs.

The Enugu State Chapter of the All Progressives Congress, APC, has asked the Economic and Financial Crimes Commission, EFCC, to tender an apology to Senator Orji Uzor Kalu. DAILY POST reports that Kalu who had been in prison custody following conviction by a High Court has now been set free by the apex court in […]

Orji Uzor Kalu deserves EFCC apology not retrial – Enugu APC

The Daesan petrochemical industrial zone in Seosan, South Chungcheong Province, will transform into an advanced chemical industrial complex. The nation's major petrochemical companies may invest up to 10 trillion won in this area. On September 14, S-Oil, Lotte Chemical, Hanwha Total, South Chungcheong provincial government, and Seosan city gathered in Lotte World Tower and signed a memorandum to create a Daesan specialized industrial complex. Currently the area is home to large petrochemical ...

“To keep me from exalting myself, there was given me a thorn in the flesh, a messenger of Satan to buffet me” (2 Corinthians 12:7).

God sometimes uses trials to humble believers.

Professional athletics, as a whole, makes up one of the least humble sectors in modern American society. Players with multi-million dollar salaries and extravagant benefits have replaced those who played because they loved their sport and had great community loyalty.

One such noble model from the past was Lou Gehrig, the Hall of Fame first baseman with the New York Yankees, whose career ended in 1939 after he was stricken with a rare and always fatal neuromuscular disease. Throughout his ordeal, Gehrig conducted himself with dignity and humility, all of which culminated on July 4, 1939, before a capacity crowd at Yankee Stadium, with millions more listening on the radio. He concluded his special remarks on “Lou Gehrig Day” with this amazing statement: “Today, I consider myself the luckiest man on the face of the earth.” He died approximately two years later.

Shouldn’t those who seek to serve and glorify God react in similar fashion if confronted by the same kind of trial? They will if they remember that He sometimes sends trials to humble His children and remind them they are not to be overconfident in their own spiritual strength (Rom. 12:3).

Today’s verse tells us God allowed Paul to be plagued by some sort of chronic, painful problem, “a messenger of Satan.” This likely refers to a man who led the opposition to Paul at the church in Corinth. When we are greatly blessed spiritually—Paul saw the risen Christ several times and was even taken up into the third heaven—the Lord sometimes allows “a thorn in the flesh” to afflict us, that we might remain humble. Whenever we are besieged by such trials and come to the point where all strength seems gone, God’s Word reminds us, as it did Paul, “‘My grace is sufficient for you, for power is perfected in weakness.’ Most gladly, therefore, I [Paul] will rather boast about my weaknesses, that the power of Christ may dwell in me” (2 Cor. 12:9).

Suggestions for Prayer

Ask the Lord to remind you throughout the day of your humble dependence on Him, whether or not you are going through a trial.

For Further Study

Read James 4:6-10 and 1 Peter 5:5-7. What do these passages say is the key to genuine humility?

From Strength for Today by John MacArthur Copyright © 1997. Used by permission of Crossway Books, a division of Good News Publishers, Wheaton, IL 60187, www.crossway.com.

• The Study Bible (mobile app)
• Grace to You Sermons (mobile app)
• John MacArthur’s complete sermon archive
• The MacArthur Study Bible
• The complete MacArthur New Testament Commentary series

“Considering the reproach of Christ greater riches than the treasures of Egypt . . .” (Hebrews 11:26).

Trials can show that material things are inadequate to meet our deepest needs.

We rely every day on material possessions—cars, computers, pagers, telephones, microwaves, radios, and TVs. These familiar conveniences make us feel as though it’s quite a hardship to cope without them. Therefore it’s difficult to avoid the pitfall Jesus warned about in Matthew 6:24, “No one can serve two masters; for either he will hate the one and love the other, or he will hold to one and despise the other. You cannot serve God and mammon [riches].”

Materialism can exert such a powerful influence on us as believers that the Lord will sometimes subject us to trials just so He can remove us from the grip of the world’s devices and riches. Various trials and sufferings will almost invariably reveal how inadequate our possessions are to meet our deepest needs or provide genuine relief from the pains and stresses of life. And this realization ought to become more and more true of you as you grow in the Christian life. I have observed that mature believers, as time goes by, become less and less attached to the temporal items they’ve accumulated. Such stuff, along with life’s fleeting experiences, simply fades in importance as you draw closer to the Lord.

Moses is a wonderful example of someone who learned through trials these important lessons about materialism (Heb. 11:24-26). He spent forty years in Pharaoh’s household and was brought up to be an Egyptian prince. But he was willing to leave a position of prestige and power so he could experience something of the sufferings of his fellow Israelites, who were living as slaves in Egypt. God in effect made Moses a participant in Israel’s trials, content to rely on Him, not on the comforts and advantages of materialism: “By faith he left Egypt, not fearing the wrath of the king: for he endured, as seeing Him who is unseen” (Heb. 11:27).

The Lord might need to get our attention in similar fashion, so that we learn one of the key lessons from life’s trials: to rely on His unlimited spiritual wealth, not on our finite and fading material possessions.

Suggestions for Prayer

Ask the Lord to make you more willing to rely on His strength and less willing to lean on material things.

For Further Study

Read 1 Timothy 6:6-11. According to Paul, what does contentment involve?

From Strength for Today by John MacArthur Copyright © 1997. Used by permission of Crossway Books, a division of Good News Publishers, Wheaton, IL 60187, www.crossway.com.

• The Study Bible (mobile app)
• Grace to You Sermons (mobile app)
• John MacArthur’s complete sermon archive
• The MacArthur Study Bible
• The complete MacArthur New Testament Commentary series

Benefiting from John's daily devotional?
Help others benefit from Grace to You.

“‘For now I know that you fear God, since you have not withheld your son, your only son, from Me’” (Genesis 22:12).

Trials from the Lord will reveal to believers what they love and appreciate the most.

A big part of the reason for the Lord’s testing Abraham at Moriah was to show him what he valued most in life. The question God wanted Abraham to answer was, “Do you love Isaac more than Me, or do you love Me more than Isaac?” And the Lord was prepared for the drastic test of taking Abraham’s son’s life if that’s what was necessary for Abraham to give God first place in everything.

God also tries the sincerity of those today who claim to love Him (see Deut. 13:3; Matt. 22:36-37). Jesus was so concerned that we have our priorities right that He made this radical statement: “If anyone comes to Me, and does not hate his own father and mother and wife and children and brothers and sisters, yes, and even his own life, he cannot be My disciple” (Luke 14:26). Christians must love Christ so much that by comparison they will seem to hate their families and themselves. In order to test this first love, God might in some dramatic fashion ask us to renounce the many tugs and appeals from family and place His will and affections first in our life.

That kind of radical obedience, which is what Abraham had, always leads to God’s blessings. Jesus Himself was a perfect example of this principle. Because He was fully human as well as fully God, our Lord did not escape ordinary pain and hardship while on earth. As the Suffering Servant (Isa. 53), He learned completely what it means to obey through pain and adversity, all the way to His crucifixion (Heb. 5:7-9). As a result, the Son was exalted by the Father (Phil. 2:8-9).

God sometimes makes our path of obedience go through the experiences of trials and sufferings. But if we are faithful to His Word and will, those difficulties will teach us to value and appreciate God’s many blessings.

Suggestions for Prayer

Pray that your priorities each day would stay in line with God’s.

For Further Study

Read Deuteronomy 6:1-9. What must be the top priority for all believers?

From Strength for Today by John MacArthur Copyright © 1997. Used by permission of Crossway Books, a division of Good News Publishers, Wheaton, IL 60187, www.crossway.com.

• The Study Bible (mobile app)
• Grace to You Sermons (mobile app)
• John MacArthur’s complete sermon archive
• The MacArthur Study Bible
• The complete MacArthur New Testament Commentary series

“To obtain an inheritance which is imperishable and undefiled and will not fade away, reserved in heaven for you” (1 Peter 1:4).

We can rejoice after enduring a trial because our hope in Heaven will be renewed.

The joy a Christian experiences as a result of trials can be the best kind he will ever know. But so often we allow the everyday stress and strain of financial difficulties, health problems, unrealized goals, and many other trials to rob us of our joy in Christ. True joy stems from spiritual realities that are much greater than temporal circumstances.

In today’s verse Peter gives us one strong reason for rejoicing—the confident hope that as Christians we have inherited a place in Heaven. This confidence can be so powerful that Peter, who was writing to believers suffering persecution, describes it as a truth we ought to “greatly rejoice” in (v. 6). This expressive, intense word is always used in the New Testament in relation to the joy of knowing God, never of shallow, temporal relationships.

Jesus’ disciples had a difficult time seeing that trials could be related to the certainty of going to Heaven. In teaching them about His upcoming death, Christ told the Twelve, “Therefore you, too, now have sorrow; but I will see you again, and your heart will rejoice, and no one takes your joy away from you” (John 16:22). And that is exactly what happened when they saw the risen Savior and understood the impact of His work.

We can have two responses to trials, just like passengers riding a train through the mountains. We can look to the left and see the dark mountainside and be depressed. Or we can look to the right and be uplifted by the beautiful view of natural scenery stretching into the distance. Some believers even compound their sadness by continuing to look to the mountain shadows of their trial after life’s train has moved away from the threatening peaks. But they would not forfeit their joy if they simply looked ahead to the brightness and certainty of their eternal inheritance.

Nothing in life can take away the wonderful promise of Heaven’s glory: it was reserved by God, bought by Christ, and guaranteed by the Spirit (see Eph. 1:11-13).

Suggestions for Prayer

Ask the Lord to help you meditate today on the glories promised for you in the future.

For Further Study

Read Revelation 21 and note the primary living conditions that will be true of Heaven.

From Strength for Today by John MacArthur Copyright © 1997. Used by permission of Crossway Books, a division of Good News Publishers, Wheaton, IL 60187, www.crossway.com.

• The Study Bible (mobile app)
• Grace to You Sermons (mobile app)
• John MacArthur’s complete sermon archive
• The MacArthur Study Bible
• The complete MacArthur New Testament Commentary series

“And after you have suffered for a little while, the God of all grace . . . will Himself perfect, confirm, strengthen and establish you” (1 Peter 5:10).

Successful endurance of present trials leads to greater focus on glorifying God in the future.

Sufferings and trials teach us patience. However, in Heaven we won’t need to have patience, and therefore it is not the major long-term lesson God wants us to learn from trials. He is far more pleased if we grasp the truth that what we suffer now is directly related to our ability to glorify Him in eternity. Worshiping God will be our role in Heaven (Rev. 4—5), and Paul reminds us that “if we endure, we shall also reign with Him” (2 Tim. 2:12). In other words, if we learn to endure trials and tribulations now, we can expect to receive great reward in eternity. I believe that reward is primarily the capacity to glorify God; and therefore the greater our present endurance, the greater will be our capability to glorify Him in the future.

At one point during Jesus’ ministry with the disciples, two of them—brothers James and John—desired that He appoint them to the two positions of greatest prestige in His kingdom—seats at His right and left hands (see Matt. 20:20-23). James and John recognized the concept of eternal rewards, but they did not understand how it works. Thus Jesus asked them if they were ready to endure the cup of suffering and death (as He was) prior to occupying such powerful positions in His kingdom (v. 22). This implies again that endurance in trials and advancement in future glory are correlated. (Jesus endured the greatest suffering on the cross, and He was raised to the highest position, at the Father’s right hand.)

The application for us from all this is clear: the Lord wants us to realize that the end of every trial contains much satisfaction and joy because we are building up our future capacity to glorify Him. At the same time, we are comprehending more and more about the value of persevering through all sorts of pain and tribulation (see Rev. 2:10).

Suggestions for Prayer

Ask God to give you the desire to see the benefits of trials from an eternal perspective.

For Further Study

Read Revelation 4—5. What attributes of God do you see, directly or indirectly, that are worthy of eternal praise?

From Strength for Today by John MacArthur Copyright © 1997. Used by permission of Crossway Books, a division of Good News Publishers, Wheaton, IL 60187, www.crossway.com.

• The Study Bible (mobile app)
• Grace to You Sermons (mobile app)
• John MacArthur’s complete sermon archive
• The MacArthur Study Bible
• The complete MacArthur New Testament Commentary series

Implications of Covid-19 on the conduct of clinical trials The current Covid-19 pandemic’s impact on European healthcare systems, such as limited or no patient contact; restricted site access; shortage of investigational medicinal products; t...

Welcome to your Diversified Industrials Sector Outlook 2019 In this outlook for the Diversified Industrials sector, we take a look at the key trends, legislation and issues we’re set to face in 2019 and the likely impact on businesses operatin...

A guide for global industrials reassessing their outsourcing requirements during coronavirus COVID-19 continues to cause widespread and indiscriminate disruption to global industrials. Manufacturing companies face more of a challenge in instituting...

The COVID-19 pandemic has taken global industrials around the world largely by surprise with wide-ranging consequences for their M&A pipelines. Coming on the back of a period of high valuations, political uncertainty and slowing deal activity, C...

The notion of testing COVID-19 vaccines by deliberately infecting volunteers with the novel coronavirus — something that’s now on the table — isn’t necessarily crazy ...

[New Era] The trial of Affirmative Repositioning (AR) land activist Dimbulukeni 'Dee' Nauyoma has been postponed to 19 May this year.

The government needs to encourage innovative technology that resonates with our requirements.

South Africa vaccinates health workers in response to the pandemic.

The murder trial over human rights lawyers, Willy Kimani death had to be postponed when lawyer, Cliff Ombeta failed to pitch in court.

Zoa took to Instagram and shared photos from the hospital while donating the blood.

FRANKFURT AM MAIN: An Indian national will stand trial in Germany accused of spying on Sikh and Kashmiri communities for New Delhi’s secret service, a court said on Friday.Federal prosecutors allege the suspect, identified as 54-year-old Balvir, has been working with the Indian foreign...

FRANKFURT: An Indian national will stand trial in Germany accused of spying on Sikh and Kashmiri communities for New Delhi’s spy agency, a court said on Friday.Federal prosecutors allege the suspect, identified as 54-year-old Balvir, has been working with the Indian foreign intelligence...

Faridabad, February 3 The newly developed Industrial Model Township (IMT) at Ballabgarh will offer nearly 530 plots to industrialists in a couple of weeks. Welcoming the move, Ramnik Prabhakar, a member of the Manufacturers Association, Faridabad (MAF), said, “We have been demanding much smaller plots, preferably of the size ranging between 50 sq yards and 300 sq yards, so that a majority of the small units operating from non-industrial areas could be adjusted in a developed township.’’ He said over 5,000 small and medium industrial units were operating from the residential and unauthorised areas and the authorities had perhaps ignored the ground realties so far. He said the rates of […]

Rep. McSally Visits Microchip Executives to Discuss Semiconductor Supply Chain Resilience in the U.S. Amid Defense Industrial Base Report Findings

A Dutch restaurant has come up with an idea on how to offer classy outdoor dining in the age of coronavirus: small glass cabins built for two or three people, creating intimate cocoons on a public...

A long-standing hypothesis suggests the BCG vaccine also serves to generally enhance the immune system, meaning it could protect against covid-19, and trials are under way to find out

Title: Children Usually Excluded From Clinical Drug Trials: Study
Category: Health News
Created: 4/30/2012 10:05:00 AM
Last Editorial Review: 4/30/2012 12:00:00 AM

Title: Analysis Finds Clinical Trials Often Small, of Poor Quality
Category: Health News
Created: 5/1/2012 6:05:00 PM
Last Editorial Review: 5/2/2012 12:00:00 AM

Title: Trial Finds Acupuncture May Help Prevent Migraines
Category: Health News
Created: 3/26/2020 12:00:00 AM
Last Editorial Review: 3/27/2020 12:00:00 AM

Machine-readability of scholarly outputs is critical to supporting large-scale analysis of the scientific literature. To that end, PMC’s Tagging Guidelines and internal processes have been updated to support the JATS4R recommendations for tagging clinical trial information. NLM encourages PMC-participating publishers, journals, and data providers to review this guidance. Please contact us at pubmedcentral@ncbi.nlm.nih.gov if you have any questions.

Title: Fewer Kids in Cancer Trials, Which Might Not Be a Bad Thing
Category: Health News
Created: 5/5/2020 12:00:00 AM
Last Editorial Review: 5/6/2020 12:00:00 AM

KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150–180 mg/m²) and pelareorep (1 x 10¹⁰ TCID₅₀–3 x 10¹⁰ TCID₅₀)] was implemented in adult patients with oxaliplatin refractory/intolerant, KRAS-mutant mCRC. Pelareorep was administered intravenously over 1 hour on days 1–5 every 4 weeks. Additional studies included pharmacokinetics, tumor morphology, and immune responses. Among FOLFIRI-naïve patients, the highest dose of FOLFIRI/bevacizumab (180 mg/m² irinotecan) and pelareorep (3 x 10¹⁰ TCID₅₀) was well tolerated, without a dose-limiting toxicity. At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively. Toxicities included myelosuppression, fatigue, and diarrhea. Transmission electron microscopy revealed viral factories (viral collections forming vesicular structures), at various stages of development. Immunogold staining against viral capsid -1 protein demonstrated viral "homing" in the tumor cells. The nucleus displayed sufficient euchromatin regions suggestive of active transcription. Flow cytometry revealed rapid dendritic cell maturation (48 hours) with subsequent activation of cytotoxic T cells (7 days). The combination of pelareorep with FOLFIRI/bevacizumab is safe. The PFS and OS data are encouraging and deserve further exploration. Pelareorep leads to a clear recurrent immune stimulatory response with cytotoxic T-cell activation, and homes and replicates in the tumor.

OBJECTIVES:

In this study, we evaluate the efficacy of Families Talking Together (FTT), a triadic intervention to reduce adolescent sexual risk behavior.

Multienvironment trials (METs) are widely used to assess the performance of promising crop germplasm. Though seldom designed to elucidate genetic mechanisms, MET data sets are often much larger than could be duplicated for genetic research and, given proper interpretation, may offer valuable insights into the genetics of adaptation across time and space. The Cooperative Dry Bean Nursery (CDBN) is a MET for common bean (Phaseolus vulgaris) grown for > 70 years in the United States and Canada, consisting of 20–50 entries each year at 10–20 locations. The CDBN provides a rich source of phenotypic data across entries, years, and locations that is amenable to genetic analysis. To study stable genetic effects segregating in this MET, we conducted genome-wide association studies (GWAS) using best linear unbiased predictions derived across years and locations for 21 CDBN phenotypes and genotypic data (1.2 million SNPs) for 327 CDBN genotypes. The value of this approach was confirmed by the discovery of three candidate genes and genomic regions previously identified in balanced GWAS. Multivariate adaptive shrinkage (mash) analysis, which increased our power to detect significant correlated effects, found significant effects for all phenotypes. Mash found two large genomic regions with effects on multiple phenotypes, supporting a hypothesis of pleiotropic or linked effects that were likely selected on in pursuit of a crop ideotype. Overall, our results demonstrate that statistical genomics approaches can be used on MET phenotypic data to discover significant genetic effects and to define genomic regions associated with crop improvement.

Background

Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).

Background

Experimental and observational studies have raised concerns that giving intravenous (IV) iron to patients, such as individuals receiving maintenance hemodialysis, might increase the risk of infections. The Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial randomized 2141 patients undergoing maintenance hemodialysis for ESKD to a high-dose or a low-dose IV iron regimen, with a primary composite outcome of all-cause death, heart attack, stroke, or hospitalization for heart failure. Comparison of infection rates between the two groups was a prespecified secondary analysis.

Background

Fluid overload in patients undergoing hemodialysis contributes to cardiovascular morbidity and mortality. There is a global trend to lower dialysate sodium with the goal of reducing fluid overload.

BACKGROUND:Ventilator-associated pneumonia (VAP) is a common and serious complication of mechanical ventilation. We conducted a meta-analysis of published randomized controlled trials to evaluate the efficacy and safety of probiotics for VAP prevention in patients who received mechanical ventilation.METHODS:We searched a number of medical literature databases to identify randomized controlled trials that compared probiotics with controls for VAP prevention. The results were expressed as odds ratios (OR) or mean differences with accompanying 95% CIs. Study-level data were pooled by using a random-effects model. Data syntheses were accomplished by using statistical software.RESULTS:Fourteen studies that involved 1,975 subjects met our inclusion criteria. Probiotic administration was associated with a reduction in VAP incidence among all 13 studies included in the meta-analysis (OR 0.62, 95% CI 0.45–0.85; P = .003; I2 = 43%) but not among the 6 double-blinded studies (OR 0.72, 95% CI 0.44–1.19; P = .20; I2 = 55%). We found a shorter duration of antibiotic use for VAP (mean difference −1.44, 95% CI −2.88 to −0.01; P = .048, I2 = 30%) in the probiotics group than in the control group, and the finding comes from just 2 studies. No statistically significant differences were found between the groups in terms of ICU mortality (OR 0.95, 95% CI 0.67–1.34; P = .77; I2 = 0%), ICU stay (mean difference –0.77, 95% CI –2.58 to 1.04; P = .40; I2 = 43%), duration of mechanical ventilation (mean difference –0.91, 95% CI –2.20 to 0.38; P = .17; I2 = 25%), or occurrence of diarrhea (OR 0.72, 95% CI 0.45–1.15; P = .17; I2 = 41%).CONCLUSIONS:The meta-analysis results indicated that the administration of probiotics significantly reduced the incidence of VAP. Furthermore, our findings need to be verified in large-scale, well-designed, randomized, multi-center trials.

Reactive immunization with a single-dose cholera vaccine that could rapidly (within days) protect immunologically naive individuals during virgin soil epidemics, when cholera reaches immunologically naive populations that have not experienced cholera for decades, would facilitate cholera control. One dose of attenuated Vibrio cholerae O1 classical Inaba vaccine CVD 103-HgR (Vaxchora) containing ≥2 x 10⁸ CFU induces vibriocidal antibody seroconversion (a correlate of protection) in >90% of U.S. adults. A previous CVD 103-HgR commercial formulation required ≥2 x 10⁹ CFU to elicit high levels of seroconversion in populations in developing countries. We compared the vibriocidal responses of Malians (individuals 18 to 45 years old) randomized to ingest a single ≥2 x 10⁸-CFU standard dose (n = 50) or a ≥2 x 10⁹-CFU high dose (n = 50) of PaxVax CVD 103-HgR with buffer or two doses (n = 50) of Shanchol inactivated cholera vaccine (the immunologic comparator). To maintain blinding, participants were dosed twice 2 weeks apart; CVD 103-HgR recipients ingested placebo 2 weeks before or after ingesting vaccine. Seroconversion (a ≥4-fold vibriocidal titer rise) between the baseline and 14 days after CVD 103-HgR ingestion and following the first and second doses of Shanchol were the main outcomes measured. By day 14 postvaccination, the rates of seroconversion after ingestion of a single standard dose and a high dose of CVD 103-HgR were 71.7% (33/46 participants) and 83.3% (40/48 participants), respectively. The rate of seroconversion following the first dose of Shanchol, 56.0% (28/50 participants), was significantly lower than that following the high dose of CVD 103-HgR (P = 0.003). The vibriocidal geometric mean titer (GMT) of the high dose of CVD 103-HgR exceeded the GMT of the standard dose at day 14 (214 versus 95, P = 0.045) and was ~2-fold higher than the GMT on day 7 and day 14 following the first Shanchol dose (P > 0.05). High-dose CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess its efficacy and practicality in field situations. (This study has been registered at ClinicalTrials.gov under registration no. NCT02145377.)